EXCLUSIVE: Plus Therapeutics Tells Benzinga Co Enters Into License Agreement For Cerebrospinal Fluid Tumor Cell Enumeration Assay
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics has entered into a license agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay. The details of the agreement were not disclosed.
September 08, 2023 | 10:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Plus Therapeutics has entered into a license agreement which could potentially expand its product portfolio and revenue streams.
The license agreement could potentially expand Plus Therapeutics' product portfolio and open up new revenue streams. This could positively impact the company's financial performance and, consequently, its stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100